Exenatide, a glucagon-like peptide-1 (GLP-1) agonist, which has a longer half-life than GLP-1 itself, is a synthetic exendin-4 compound that belongs to a class of diabetes treatments known as incretin mimetics, which work by mimicking the glucose lowering actions of naturally occurring human hormones (such as GLP-1) called incretins.